Genky DrugStores Co., Ltd. (9267) AI Stock Analysis

• Market Cap: ¥137.42B
• Dividend Yield: 0.25%
• Average Volume (3M): 62.69K
• Price to Earnings (P/E): 18.1
• Beta (1Y): 0.23
• Revenue Growth: 9.97%
• EPS Growth: 16.27%
• Country: JP
• Employees: 1,661
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 67.01
• Shares Outstanding: 31,009,169
• 10 Day Avg. Volume: 60,060
• 30 Day Avg. Volume: 62,690
• PEG Ratio: 1.39
• Price to Book (P/B): 2.17
• Price to Sales (P/S): 0.58
• P/FCF Ratio: -46.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 73 Outperform
• Price Target: ¥6,024.00 ▲(21.45% Upside)

Genky DrugStores Co., Ltd. shows strong financial performance with consistent revenue growth and profitability, which is the most significant factor in the overall score. The technical analysis indicates a bullish trend, supporting the positive outlook. However, the valuation is only fair, with a low dividend yield, which slightly tempers the overall score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates a strong market position and effective business strategies, supporting long-term financial stability.

Market Position

A large store network enhances market reach and customer convenience, solidifying Genky's competitive advantage in the retail sector.

Profit Margins

Strong profit margins reflect operational efficiency and pricing power, contributing to sustainable profitability over time.

Negative Factors

Negative Free Cash Flow

Negative free cash flow suggests potential liquidity issues, which could impact the company's ability to invest in growth and manage debt.

Cash Flow Management

Poor cash flow management can strain financial resources, limiting the company's ability to fund operations and strategic initiatives.

Dividend Yield

A low dividend yield may deter income-focused investors, potentially affecting the company's stock attractiveness and market valuation.

Genky DrugStores Co., Ltd. Business Overview & Revenue Model

Company Description

Genky DrugStores Co., Ltd. operates a chain of drug stores. The company was founded in 1988 and is headquartered in Sakai, Japan.

How the Company Makes Money

Genky DrugStores generates revenue primarily through the sale of a diverse array of products in its drugstores, which include prescription medications, over-the-counter drugs, personal care items, and groceries. The company's revenue model is built on high sales volume, driven by its extensive store network and strategic location choices that cater to consumer convenience. Key revenue streams include retail sales, which are bolstered by promotional campaigns, loyalty programs, and seasonal marketing strategies. Additionally, Genky may benefit from supplier partnerships, allowing for favorable purchasing terms and exclusive product offerings that enhance profit margins. The company's focus on expanding its footprint through new store openings and optimizing existing locations also contributes significantly to its earnings.

Genky DrugStores Co., Ltd. Financial Statement Overview

Summary

Genky DrugStores Co., Ltd. demonstrates a strong financial position with consistent revenue growth and profitability. The balance sheet reflects a stable leverage position, while the income statement shows robust margins. However, the negative free cash flow highlights a need for improved cash management strategies. Overall, the company is on a positive trajectory but should focus on enhancing cash flow stability.

Income Statement

Genky DrugStores Co., Ltd. has shown consistent revenue growth with a 4.51% increase in the latest year. The gross profit margin is healthy at approximately 20.36%, and the net profit margin has improved to 3.52%. EBIT and EBITDA margins are also stable, indicating strong operational efficiency. Overall, the income statement reflects a robust financial performance with positive growth trends.

Balance Sheet

The company's debt-to-equity ratio has improved over the years, currently at 0.64, indicating a balanced leverage position. The return on equity is strong at 13.55%, showcasing effective use of equity to generate profits. The equity ratio is stable, suggesting a solid financial structure. However, the company should continue monitoring its debt levels to maintain financial stability.

Cash Flow

Operating cash flow remains strong, but the free cash flow has turned negative, indicating potential challenges in cash generation after capital expenditures. The operating cash flow to net income ratio is healthy, but the negative free cash flow growth rate of -191.53% is a concern. The company needs to address its cash flow management to ensure long-term sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	200.79B	200.79B	184.86B	169.06B	154.64B	142.38B
Gross Profit	40.89B	40.89B	37.62B	34.55B	30.95B	30.29B
EBITDA	16.23B	16.41B	14.47B	11.73B	10.73B	10.78B
Net Income	7.07B	7.07B	6.32B	4.76B	4.42B	4.83B
Balance Sheet
Total Assets	127.33B	127.33B	113.94B	105.91B	97.12B	90.80B
Cash, Cash Equivalents and Short-Term Investments	6.22B	6.22B	5.90B	5.33B	5.44B	7.91B
Total Debt	34.37B	34.37B	30.65B	32.35B	30.96B	28.56B
Total Liabilities	73.89B	73.89B	67.26B	65.23B	60.88B	58.63B
Stockholders Equity	53.43B	53.43B	46.68B	40.68B	36.23B	32.17B
Cash Flow
Free Cash Flow	0.00	-2.50B	2.81B	-1.16B	-4.43B	3.12B
Operating Cash Flow	0.00	12.60B	13.26B	8.77B	6.08B	12.08B
Investing Cash Flow	0.00	-15.62B	-10.63B	-9.74B	-10.59B	-8.83B
Financing Cash Flow	0.00	3.35B	-2.06B	854.00M	2.04B	-1.95B

Genky DrugStores Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4960.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9267, the sentiment is Negative. The current price of 4960 is below the 20-day moving average (MA) of 4976.17, below the 50-day MA of 4995.85, and above the 200-day MA of 4267.23, indicating a neutral trend. The MACD of -83.04 indicates Positive momentum. The RSI at 26.65 is Positive, neither overbought nor oversold. The STOCH value of 7.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:9267.

Genky DrugStores Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7649	75 Outperform	¥695.85B	15.80	15.71%	0.96%	21.81%	67.76%
9267	73 Outperform	¥137.42B	18.09	―	0.25%	9.97%	16.27%
9989	69 Neutral	¥491.31B	15.48	11.50%	3.04%	6.32%	8.19%
3391	67 Neutral	¥1.16T	28.80	―	1.72%	―	―
3549	67 Neutral	¥428.36B	23.99	―	0.41%	15.81%	27.05%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Genky DrugStores Co., Ltd. Corporate Events

Genky DrugStores Posts Double-Digit Sales Growth as Store Network Expands to 499 Locations

In December of the fiscal year ending June 2026, Genky DrugStores reported solid growth, with all-store net sales up 10.6% year on year and existing-store sales up 3.3%, driven mainly by a 2.7% increase in customer traffic and a modest rise in spending per customer. For the first half of the fiscal year, all-store sales rose 10.6% and existing-store sales 4.2%, as the company accelerated its expansion to 499 locations by year-end through 20 new store openings and ongoing refurbishment of larger outlets into standardized regular stores, underscoring a strategy of disciplined footprint growth and format standardization that supports steady same-store performance.

The most recent analyst rating on (JP:9267) stock is a Buy with a Yen6024.00 price target. To see the full list of analyst forecasts on Genky DrugStores Co., Ltd. stock, see the JP:9267 Stock Forecast page.

Genky DrugStores Reports Strong Q3 Financial Performance

Genky DrugStores Co., Ltd. reported a strong financial performance for the three months ended September 20, 2025, with significant increases in net sales and income compared to the previous year. The company’s robust growth in operating and ordinary income reflects its solid market positioning and effective operational strategies, which are expected to continue supporting its financial stability and stakeholder confidence.

The most recent analyst rating on (JP:9267) stock is a Buy with a Yen5046.00 price target. To see the full list of analyst forecasts on Genky DrugStores Co., Ltd. stock, see the JP:9267 Stock Forecast page.

Genky DrugStores Completes Treasury Stock Disposal for Compensation

Genky DrugStores Co., Ltd. has completed the payment procedure for the disposal of 69,000 shares of its treasury stock as restricted stock compensation. This move involves a total transaction amount of 336,030,000 Yen, with shares allocated to directors and subsidiary employees, potentially impacting the company’s financial structure and stakeholder interests.

The most recent analyst rating on (JP:9267) stock is a Buy with a Yen5046.00 price target. To see the full list of analyst forecasts on Genky DrugStores Co., Ltd. stock, see the JP:9267 Stock Forecast page.